What type of study is this?

October 17, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis

View Full Paper

Ask AI

Bookmark

Authors

YLYang LiuGuangzhou University of Chinese Medicine JBJianping BiAffiliated Hospital of Shandong University of Traditional Chinese Medicine XDXuelin DouPeking University

Discussion

Member takes

Implication

Multicenter study shows dFLC decrease predicts complete hematologic response and organ responses in AL amyloidosis patients on daratumumab-bortezomib therapy.

Key Points

Profound decrease in dFLC after one cycle predicts high complete hematologic response rates in AL amyloidosis patients.
Patients with >87% dFLC reduction had a 90.5% rate of complete hematologic response versus 43.5% in those with lower reductions.
ROC analysis identified dFLC reduction as a significant predictor of treatment response post one cycle of therapy.
Early identification of optimal responders supports potential early treatment modifications for better patient outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68f199d1de32064e504dd76f https://doi.org/10.1080/10428194.2025.2571200

View Full Paper

Ask AI

Bookmark

Implication

Multicenter study shows dFLC decrease predicts complete hematologic response and organ responses in AL amyloidosis patients on daratumumab-bortezomib therapy.

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider